… 's largest stock CSL (ASX:CSL) this week after its … will need patience. "CSL is the cornerstone of defensive … weighing near term but CSL Vifor and CSL Behring are intact.… brain activity in people with drug-resistant epilepsy. Minder facilitates …

… comes just two days after CSL announced it was delaying … will also work with domestic drugmaker Vaccine Industrial Company to set … influenza.”   Earlier this year, CSL announced plans to spin off … 39;s general meeting Tuesday, CSL's chairman revealed that …

… the world. On Thursday, CSL announced that CSL Seqirus and Vaccine Industrial … seasonal influenza.” Meldrum continued, “CSL Seqirus is an influenza pandemic … #47;business/healthcare-pharmaceuticals/;australias-csl-delays-vaccine-division-spin-off …

… the International Society for Pharmaceutical Engineering (ISPE) and … The CSL Behring facility also won FOYA’s Pharma 4 … 2023, respectively.  Related:Pharma tariffs under Trump: Industry … Tara Dougal, Events Director, Pharma Portfolio, Informa Markets, discussed …

Some of CSL’s biggest shareholders are refusing … on their outlook for the pharmaceutical giant despite more than $40 … . After fund managers jumped into CSL in the aftermath of a …

… growth, lifting the British drugmaker';s shares to their … early next year, with the drugmaker navigating US tariffs and seeking … as some top-selling drugs go off patent. Pressure in … due to competition. Australian biotech CSL on Tuesday delayed plans to …

CSL has said that with flu … facilities in its plasma business. CSL's already depressed share … ," he told the meeting. CSL cuts its full-year revenue … .6 billion, driven by haemophilia drugs and plasma-derived therapies, while …

… Rhys Grinter is transforming drug development by harnessing Nobel … the lab, delivering potential drugs many times faster than … fast-track drugs to patients. Dr Michael Wilson, CSL Senior Vice … and drug discovery. “With the support of the CSL Centenary …

… digit growth, lifting the British drugmaker’s shares. Although U.S … early next year, with the drugmaker navigating U.S. tariffs … declines as some top-selling drugs go off patent. PRESSURE … due to competition. Australian biotech CSL on Tuesday delayed plans to …

… plans are on track   CSL (ASX:CSL) analysts haven’t exactly given … administration’s ‘most favoured nation’ drug pricing policy. Broker Morgans also … board. “These appointments position LTR Pharma to enable prescriber adoption and …